/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced.
This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of Onxeo's current and future programs Regulatory News: Onxeo